Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Real-world evidence and regulatory drug approval

Nature Reviews Clinical Oncology volume 17, pages 271–272 (2020)Cite this article

Subjects

The FDA has demonstrated a willingness to expedite access to new cancer medicines by using real-world evidence to support regulatory drug approval. In this article, we explore three recent examples of such approvals and the lessons that can be learned from this collective experience.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57–66 (2015).

    Article  CAS  Google Scholar 

  2. Przepiorka, D. et al. FDA approval: blinatumomab. Clin. Cancer Res. 21, 4035–4039 (2015).

    Article  CAS  Google Scholar 

  3. Gokbuget, N. et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101, 1524–1533 (2016).

    Article  Google Scholar 

  4. Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836–847 (2017).

    Article  CAS  Google Scholar 

  5. Pease, A. M. et al. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 357, j1680 (2017).

    Article  Google Scholar 

  6. Center for Drug evaluation and Research. Approval Package for: Application number: 761049Orig1s000 fda.gov https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761049Orig1s000Approv.pdf (2017).

  7. Wedam, S. et al. FDA approval summary: palbociclib for male patients with metastatic breast cancer. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-2580 (2019).

    Article  PubMed  Google Scholar 

  8. Bartlett, C. H. et al. Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET) [abstract]. J. Clin. Oncol. 37 (Suppl. 15), 1055 (2019).

    Article  Google Scholar 

  9. Weiss, J. R., Moysich, K. B. & Swede, H. Epidemiology of male breast cancer. Cancer Epidemiol. Biomarkers Prev. 14, 20–26 (2005).

    Article  Google Scholar 

  10. Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012).

    Article  CAS  Google Scholar 

  11. Gounder, M. M. et al. Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105) [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 11500 (2018).

    Article  Google Scholar 

  12. Escobar, C., Munker, R., Thomas, J., Li, B. D. & Burton, G. V. Update on desmoid tumors. Ann. Oncol. 23, 562–569 (2011).

    Article  Google Scholar 

Download references

Acknowledgements

The work of C.M.B. is supported as the Canada Research Chair in population Cancer Care.

Author information

Authors and Affiliations

  1. Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute, Kingston, Canada

    Michael J. Raphael, Bishal Gyawali & Christopher M. Booth

  2. Department of Oncology, Queen’s University, Kingston, Canada

    Michael J. Raphael, Bishal Gyawali & Christopher M. Booth

  3. Department of Public Health Sciences, Queen’s University, Kingston, Canada

    Michael J. Raphael, Bishal Gyawali & Christopher M. Booth

  4. Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Bishal Gyawali

Authors
  1. Michael J. Raphael
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bishal Gyawali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher M. Booth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher M. Booth.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raphael, M.J., Gyawali, B. & Booth, C.M. Real-world evidence and regulatory drug approval. Nat Rev Clin Oncol 17, 271–272 (2020). https://doi.org/10.1038/s41571-020-0345-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-020-0345-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer